All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
MUNDESINE® (forodesine hydrochloride) approved by Japan’s MHLW for relapsed or refractory Peripheral T-Cell Lymphoma
Bookmark this article
On 30th March 2017, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved MUNDESINE® (forodesine hydrochloride) for the treatment of Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL).
Mundipharma’s MUNDESINE® is an orally administered Purine Nucleoside Phosphorylase (PNP) inhibitor, and this approval is the first in the world for this type of agent. PNP inhibition results in increased levels of 2'-deoxyguanosine and buildup of intracellular deoxyguanosine 5'-triphosphate, initiating apoptosis.2
The compound is the first oral monotherapy for this indication and also holds Orphan Drug status in Japan. The approval is based on successful clinical trials.
- Mundipharma’s mundesine approved in Japan. 2017 Apr 03. https://www.biocentury.com/bc-extra/company-news/2017-04-03/mundipharmas-mundesine-approved-japan. [Accessed 2017 Apr 06].
- Furman R.R. & Hoelzer D. Purine nucleoside phosphorylase inhibition as a novel therapeutic approach for B-cell lymphoid malignancies. Seminars in Oncology. 2007 Dec; 34(6 Suppl 5):S29–34.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youYour opinion matters
44 votes - 79 days left ...
Related articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox